Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban anticoagulation in very elderly patients
ChiCTR-IPR-17011918Phase 4Recruiting
- Sponsor
- Xinhua Hospital
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rivaroxaban in thrombosis, Atrial fibrillation (AFib), pulmonary embolism (PE) and 1 more (2 arms), sponsored by Xinhua Hospital. Primary endpoint: Major bleeding. Started Jul 2017; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
thrombosisAtrial fibrillation (AFib)pulmonary embolism (PE)deep vein thrombosis (DVT)
Beyond the preview
Go deeper on ChiCTR-IPR-17011918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17011918.